权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Sustained Suprachoroidal Delivery of Therapeutic Peptidesfor Ocular Diseases

治疗性肽持续脉络膜上递送治疗眼部疾病

基本信息

批准号：
9317491
负责人：
Peter A Campochiaro
金额：
$ 20.44万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2019-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9317491
关键词：
Affect Age Animal Disease Models Animal Model Blindness Blood Vessels Choroidal Neovascularization Complications of Diabetes Mellitus Computer Simulation Computing Methodologies Convection Development Diabetic Retinopathy Diffuse Diffusion Dimensions Disadvantaged Disease Drug Delivery Systems Edema Evaluation Extravasation Exudative age-related macular degeneration Eye Feedback Frequencies Goals Growth Factor Human In Situ Injectable Injection of therapeutic agent Label Laboratories Liquid substance Measures Medical Modeling Mus New Agents Oryctolagus cuniculus Patients Peptide Transport Peptides Permeability Pharmaceutical Preparations Physiological Plasma Preparation Proteins Reaction Regimen Research Proposals Retina Retinal Neovascularization Retinal Vein Occlusion Schedule Testing Therapeutic Time Tissues Vascular Endothelial Growth Factors Vascular Permeabilities Visual impairment angiogenesis comparative efficacy design experimental study improved in vivo intravitreal injection macula macular edema multidisciplinary neovascularization particle peptide drug pre-clinical prevent retina blood vessel structure simulation

项目摘要

Summary: Current therapies for neo-vascular age-related macular degeneration and macular edema are injected directly into the vitreous on a monthly or bi-monthly schedule. There is a great need for new agents with improved efficacy as well as other modes of delivery for less frequent administration. We have developed peptides with potent activity in animal models of these diseases as well as sustained delivery vehicles which are able to release the peptides in a controlled manner for multiple months. Here we propose to test the hypothesis that our sustained delivery drug can be injected successfully into the suprachoridal space behind the retina from which the active peptides will be released into the affected tissues to inhibit neovascularization and edema. Computational modeling will be used to quantify the drug delivery and extend it to a model of the human eye. The proposal is multidisciplinary and is greatly strengthened by the team's expertise in animal models, particle design and fabrication, peptide development, and computational methods.

总结：目前用于新生血管性年龄相关性黄斑变性和黄斑水肿的疗法是按每月或每两个月的时间表直接注射到玻璃体中。非常需要具有改善功效的新药剂以及用于频率较低的其他给药模式局我们已经开发出在这些动物模型中具有有效活性的肽，疾病以及能够以可接受的方式释放肽的持续递送载体。控制方式持续数月。在这里，我们提出测试的假设，我们的可将持续递送药物成功地注射到脉络膜后的脉络膜上间隙中，活性肽将从视网膜释放到受影响的组织中以抑制新血管形成和水肿。计算建模将用于量化药物并将其扩展到人眼模型。该提案是多学科的，该团队在动物模型、粒子设计和制造方面的专业知识大大加强了这一点，肽开发和计算方法。